JAMES MCLEMORE: Open Payments
NPI 1831734599 · OLYMPIA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,025 in 49 payments from 12 companies in 2025. Trend: 2023 $185 · 2024 $801 · 2025 $1,025
Food & beverage: $1,025
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $206 |
| Janssen Pharmaceuticals, Inc | 7 | $182 |
| Otsuka America Pharmaceutical, Inc. | 7 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $109 |
| E.R. Squibb & Sons, L.L.C. | 4 | $101 |
| Alkermes, Inc. | 3 | $67 |
| Braeburn Inc. | 3 | $60 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Indivior Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
Products named: REXULTI, CAPLYTA, COBENFY, SPRAVATO, AUSTEDO XR, INVEGA SUSTENNA, ARISTADA, BRIXADI.
Industry payments across WA — which companies pay providers there.
